This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Florida A&M University (FAMU) Research Center in Minority Institutions (RCMI) Abstract This application seeks to continue the evolution of the Pharmaceutical Research Center at Florida A&M University (FAMU). The previously funded targeted research activities have demonstrated productivity and resulted in significant discoveries that have led to the award of several patents and additional pending discoveries. Based on the evaluation of the current research infrastructure and the strategic needs of the program, it is proposed to transition the targeted activities into the development of Core research facilities. The main objective of the current application is to build the infrastructure of the research program towards more understanding of the mechanistic details of the molecular system. This RCMI center will focus efforts on approaches, i.e., gene expression analysis, proteomics, PCR analysis, gene delivery systems and DNA microarray techniques. The establishment of Core facilities in the areas of molecular neurobiology, cellular imaging, neurochemistry/receptors, flow cytometer and Nanomedicine will increase our abilities to understand the mechanistic details of the molecular system and to provide greater insights into how the different molecular are modulated under disease and adverse conditions. The Pharmaceutical Research Center will consist of a research administrative component coupled with three (3) core service delivery facilities. The administrative component will continue to provide pre- and post- award assistance, coordinate the activities of the external and internal advisory committee, provide scientific seminars and grants workshops, coordinate a new structured mentoring program, facilitate an extensive external evaluation of program outcomes, assist in faculty development, hire a research faculty member and market and conduct an on-site grants management workshop and the annual RCMI R01 Scientist Seminar Series.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12RR003020-27
Application #
8357109
Study Section
Special Emphasis Panel (ZRR1-RI-3 (01))
Project Start
2011-06-01
Project End
2012-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
27
Fiscal Year
2011
Total Cost
$514,997
Indirect Cost
Name
Florida Agricultural and Mechanical University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
623751831
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Poku, Rosemary A; Salako, Olufisayo O; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors induce caspase 3/7- and 8-mediated apoptosis and inhibit migration and invasion of metastatic prostate cancer cells. Am J Cancer Res 7:1515-1527
Ntantie, Elizabeth; Fletcher, Jerrine; Amissah, Felix et al. (2017) Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer. Oncotarget 8:31726-31744
Mazzio, Elizabeth A; Soliman, Karam F A (2017) HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells. Cancer Genomics Proteomics 14:17-33
Godugu, Chandraiah; Doddapaneni, Ravi; Patel, Apurva R et al. (2016) Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharm Res 33:137-54
Mochona, Bereket; Jackson, Timothy; McCauley, DeCoria et al. (2016) Synthesis and Cytotoxic Evaluation of Pyrrole Hetarylazoles Containing Benzimidazole/Pyrazolone/1,3,4-Oxadiazole Motifs. J Heterocycl Chem 53:1871-1877
Mazzio, Elizabeth A; Li, Nan; Bauer, David et al. (2016) Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med 16:467
Etukala, Jagan R; Zhu, Xue Y; Eyunni, Suresh V K et al. (2016) Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem 24:3671-9
Nkembo, Augustine T; Ntantie, Elizabeth; Salako, Olufisayo O et al. (2016) The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget 7:68194-68205
Boakye, Cedar H A; Patel, Ketan; Doddapaneni, Ravi et al. (2016) Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention. Colloids Surf B Biointerfaces 143:156-167
Odewumi, Caroline O; Latinwo, Lekan M; Ruden, Michael L et al. (2016) Modulation of cytokines and chemokines expression by NAC in cadmium chloride treated human lung cells. Environ Toxicol 31:1612-1619

Showing the most recent 10 out of 204 publications